Introduction YNIOS Pharma srl operates a biotechnology platform that aims to offer treatments for various acute and chronic conditions. Their platform employs a unique ionic compound to create novel oral and parenteral therapies for diseases resulting from inflammation-induced neuronal degeneration. Additionally, the company supports the preclinical development of multiple pathologies associated with both acute and chronic inflammation, ultimately providing patients with more efficient and better-tolerated treatment options. |






